




EMA Emergency Task Force update

HCPWP and PCWP representative report: Anita Simonds (ERS), Jose Drabwell (IPOPI)

September 19 2023


HCP Emergency Task Force remit

- Originally became member of Emergency Covid Task Force from Oct 2020 jointly with Dr Tiago Villanueva, GP from UEMO based in Portugal.
- I work across Respiratory Medicine, ICU and HDU care (ERS). We both had frontline clinical and research covid experience
- Covid Task Force morphed into Emergency Task Force April 2022, and Tiago stepped down a few months ago. ETF handled MPox as well as covid in Summer 2022, interesting to see application of EMA extended remit to rapidly set up EU trials for antivirals and vaccine in Mpox. Now influenza discussions.
- Initially virtual meetings 3 x week. Now usually once (or twice) a week




HCP representative on ETF roles

- Responsibilities: ETF meeting attendance for transparency, governance and clinical purposes
- I have attended 94 Covid TF meetings, and 52 Emergency TF meetings since Oct 2020
- Role: 2 way - comment on clinical aspects of trials, voting rights for decision-making, dissemination of information and updates to HCPs
- Attend Workshops eg on vaccine-induced myocarditis, VITT
- Comms: Input on SAE reports on Covid Vaccines
- Comms: European Vaccine Day 'Catch up on vaccines' campaign - video for social media
- Advocate on behalf of EMA to combat disinformation and misinformation, and to facilitate better HCP understanding of EMA processes



Flows



Scope

Examples of recent ETF discussions

- Scientific advice on trial processes
- Update on covid variants, new vaccine platform plans, 'pan' vaccines
- New Autumn/Winter season covid campaigns
- Seasonal influenza vaccine - children, adults
- Updates on covid vaccine outcomes in immunosuppressed, Tx patients, pregnancy - *v imp to HCPs and Patients*
- Due: workshop on long covid, joint HERA meeting on countermeasures for chemical biological, radiological threats

Reflections: Positives and negatives

- Hugely informative
- Can watch decision-making in action
- Collegiate approach as input from multiple highly experienced rapporteurs, regulatory authorities; now closer links to trial design and academia, balanced approach to industry
- Steep learning curve, multiple acronyms!
- Identifying dissemination routes to HCPs

PCWP participation in ETF meetings

- **For quite some time I have represented the PCWP in the ETF meetings**
- **It has been a steep learning curve as the Task Force deals with issues, which are not normally discussed at a patient organisation's meeting and many of the topics are confidential.**
- **I feel that my remit is to always approach a discussion with a patient's point of view. To highlight the population with special requirements, such as pregnant woman, young children and the immunocompromised patients.**
- **There are discussions on the subject of possible treatments for Sars2-COVID, FLU vaccinations for various age groups.**
- **Future developments and agenda items are shared among the ETF members and quite often and hoc documents need to be commented on quickly.**
- **I hope that the Taskforce has found the input of both patients and health care professionals of value.**